Surgical Sciences Department, School of Dentistry, Marquette University, Milwaukee, Wisconsin, USA.
Department of Biomedical and Surgical and Biomedical Sciences, Catania University, Catania, Italy.
J Oral Rehabil. 2023 Sep;50(9):845-851. doi: 10.1111/joor.13487. Epub 2023 May 18.
Condylar hyperplasia (CH) is a rare condition characterised by excessive unilateral growth of the mandibular condyle after cessation of growth on the contralateral side causing facial asymmetry, being more prevalent in the second and third decades.
The aim of this study was to determine the utility of vascular endothelial growth factor (VEGF-A) as a diagnostic and prognostic factor in condylar hyperplasia, and to determine its potential viability as a therapeutic target.
This is a case-control study, where 17 mandibular condyles specimens were collected from 17 patients treated for active mandibular condyle hyperplasia and three unaffected human mandibular condyles from cadavers will serve as the control group. The samples were immunostained with VEGF-A antibody and evaluated on both quantity and intensity of staining.
VEGF-A was qualitatively found to be greatly upregulated in patients with condylar hyperplasia.
VEGF-A was qualitatively found to be upregulated in patients affected by CH, validating VEGF-A as a potential diagnostic, prognostic and therapeutic target.
髁突增生症(CH)是一种罕见病症,其特征为生长停止后,患侧下颌髁突过度生长,导致面部不对称,好发于第二和第三个十年。
本研究旨在确定血管内皮生长因子(VEGF-A)作为诊断和预后因子在髁突增生症中的作用,并确定其作为治疗靶点的潜在可行性。
这是一项病例对照研究,共收集了 17 例接受活动期下颌髁突增生症治疗的患者的 17 个下颌髁突标本,以及三个来自尸体的正常人类下颌髁突作为对照组。用 VEGF-A 抗体对标本进行免疫染色,并对染色的数量和强度进行评估。
在髁突增生症患者中,VEGF-A 的表达被定性为显著上调。
在患有 CH 的患者中,VEGF-A 被定性为上调,验证了 VEGF-A 作为潜在的诊断、预后和治疗靶点的作用。